Price (delayed)
$1.1
Market cap
$48.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.21
Enterprise value
$73.97M
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.
There are no recent dividends present for EIGR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.